Psychedelics vs. Antidepressants: What the 2026 JAMA Psychiatry Data Actually Shows
By Dr. Anindo Mitra | MBBS, MD Psychiatry (JIPMER) | Consultant Psychiatrist, Athena Behavioural Health, Gurugram
Published on dranindomitra.com | Reading time: ~20 minutes
TL;DR
A March 2026 JAMA Psychiatry meta-analysis found psychedelic-assisted therapy and open-label antidepressants produced equivalent depression score reductions — roughly 12 points on the Hamilton Depression Rating Scale
The key insight: psychedelic trials are functionally unblinded (up to 90–95% of participants know they received the active drug), so comparing them to blinded antidepressant trials was always methodologically unfair
When compared against open-label antidepressant trials — a like-for-like comparison — the advantage of psychedelics disappears
This doesn't mean psychedelics don't work. It means expectancy effects are a significant and previously underappreciated driver of their apparent superiority
The honest clinical read: psychedelics remain a promising but still-evolving tool, not a replacement for conventional treatment
The Psychedelics vs. antidepressants: the direct comparison
There is no clean head-to-head answer. Psychedelics and antidepressants are not interchangeable treatments pointing at the same patients. They differ in mechanism, delivery, evidence maturity, and the practical reality of access. The question "which is better?" assumes a single comparison is possible. It isn't.
Mechanism SSRIs and SNRIs work by increasing synaptic serotonin (and noradrenaline) availability, with receptor-level changes building over weeks. Psilocybin acts as a direct 5-HT2A agonist, producing rapid neuroplasticity effects and disrupting default mode network activity — the brain network associated with rumination and self-referential thought.
Onset SSRIs typically require 2–6 weeks for a clinical response and 8–12 weeks for full effect. Psilocybin produces subjective effects within hours; trials have reported antidepressant signals at 1–3 weeks, though how much of that is pharmacological versus expectancy-driven is precisely what the March 2026 JAMA Psychiatry meta-analysis questioned.
Evidence quality SSRIs have a moderate-to-high evidence base for short-term efficacy, with long-term data available — though that data carries its own problems (publication bias, industry influence, short washout periods). Psilocybin evidence is currently rated low to moderate: RCTs are small, blinding is structurally compromised, and follow-up rarely extends beyond 3–6 months.
Durability Some psilocybin trials report sustained benefit at 3–6 months after a single session. Data beyond 12 months is sparse. SSRIs require ongoing dosing; relapse rates after discontinuation are significant, particularly in recurrent depression.
Legal status in India SSRIs and SNRIs are prescription medications, widely available. Psilocybin is a Schedule I controlled substance under the NDPS Act. There are no approved clinical settings for psychedelic-assisted therapy in India.
Who each currently fits Psilocybin-assisted therapy, in the trial evidence available, has shown the most signal in adults with treatment-resistant depression who have not responded to at least two adequate antidepressant trials. It requires a psychologically intensive setting, adequate psychosocial support, and is not appropriate for those with a personal or family history of psychosis or bipolar I disorder. For most patients in India, access outside a research context does not exist.
SSRIs and SNRIs remain the practical first-line option for moderate-to-severe depression, including patients who need long-term maintenance, those with comorbid anxiety, and anyone for whom daily functioning, cost, and access are real constraints.
The headline That Wasn't Quite Right
Psychedelic-assisted therapy is not more effective than antidepressants. That's what a meta-analysis published on 18 March 2026 in JAMA Psychiatry concluded — and the headline spread fast.
Before filing that away as another cycle of hype and disappointment, it's worth reading what the study actually did. Because the finding is genuinely interesting, but not quite in the way the headlines suggested.
What the Study Actually Did
For decades, SSRIs and SNRIs have been the dominant medications prescribed for depression. Psychedelics are often promoted as a more effective or "natural" alternative — but the comparison has always rested on a methodological mismatch.
Standard antidepressant trials are double-blind. Participants don't know if they received the active drug or a placebo. Psychedelic trials have a well-known blinding problem: the drugs are so experientially obvious that 90–95% of participants know they've received the active substance.
This matters enormously. If you know you've taken a psychedelic, you approach the experience with a different set of expectations — and in psychiatry, expectations are not trivial. They are partially therapeutic.
The meta-analysis authors addressed this directly. They compared psychedelic-assisted therapy (PAT) against open-label SSRI and SNRI studies — trials where participants knew whether they were receiving an antidepressant or placebo. Their logic: since all PAT studies are essentially open-label by nature, the fair comparison is against open-label antidepressant trials, not blinded ones. The analysis drew on data from 24 studies covering more than 8,000 patients.
What They Found — and What It Means
When the like-for-like comparison was made, the advantage of psychedelics disappeared. Both groups showed equivalent improvement — roughly a 12-point drop on the Hamilton Depression Rating Scale. The difference between them: 0.3 points. Statistically meaningless.
Even the senior author acknowledged this wasn't the finding he expected: "What I wanted to show is that even if you compare psychedelics to open-label antidepressants, psychedelics are still much better."
What this actually demonstrates is not that psychedelics fail. It's that expectancy — knowing you've received an active treatment and expecting it to help — accounts for a meaningful proportion of the antidepressant effect seen in psychedelic trials.
James Rucker of King's College London offered a measured interpretation: "In some ways this is reassuring, as it reconfirms that psychedelic therapy probably does have a true antidepressant effect. On the other hand, it also suggests that a significant part of this effect is mediated by a positive expectancy effect derived from a participant knowing that they are receiving treatment."
This is the most important sentence in the coverage of this study — and it barely appeared in the headlines.
Why Expectancy Effects Are a Serious Clinical Issue — Not a Dismissal
Expectancy effects are not placebo in the dismissive sense. They are a real neurobiological phenomenon — involving dopaminergic and opioidergic pathways — and they are clinically significant across medicine, not just psychiatry.
But in a clinical trial trying to isolate a drug's pharmacological effect, expectancy becomes a confound. If a drug produces large benefits primarily because participants believe it will work — and that belief is driven by the dramatic, unmistakable experience of taking the drug — you cannot attribute those benefits cleanly to neurochemistry.
For psychedelics, this problem is structural. The drug is its own unblinding mechanism. Participants in the placebo arm of psychedelic trials often experience disappointment at realising they received an inactive substance — pushing their outcomes lower and further inflating the apparent advantage of the active arm. Both directions of this bias compound each other.
You can read more about how psychiatric clinical trials are designed and why blinding matters on our blog.
The Counter-Argument Deserves to Be Heard
This study has been challenged — and not without reason.
Robin Carhart-Harris, a leading psychedelic researcher, describes the overall comparison as an "indefensible deck stack," arguing the antidepressant data is contaminated by legacy trial-design flaws absent from psychedelic data.
His central objection concerns washout periods. Many of the open-label antidepressant trials included in the meta-analysis allowed patients only a one-to-two week washout from their previous antidepressants before starting the study drug. When a patient stops an antidepressant abruptly, discontinuation effects temporarily worsen symptoms — pushing baseline scores artificially high. When they then restart a new antidepressant, symptoms drop rapidly, not because the new drug is especially effective, but because they're rebounding from withdrawal.
This is a legitimate concern. If the antidepressant comparison arm is artificially inflated by withdrawal rebound, then the "equivalence" between psychedelics and antidepressants may itself be a methodological artefact.
The honest answer: both critiques may be partially correct. Psychedelic trials overestimate effect due to expectancy. Antidepressant open-label trials may overestimate effect due to washout artefact. The meta-analysis corrects for one; critics argue it introduced another.
What the EPISODE Trial Adds
A second study published simultaneously in JAMA Psychiatry — the EPISODE trial — was a rigorously designed randomised clinical trial that also attempted to address the blinding problem. It found tentative support for the antidepressant effects of high-dose psilocybin, though effects were relatively temporary in most cases.
The EPISODE trial missed its primary endpoint — at least a 50% improvement in depressive symptoms with high-dose psilocybin plus psychotherapy — but found clinically meaningful benefit on some secondary measures. The authors concluded: "Although results suggest potential efficacy, the divergence between primary and secondary outcomes renders the findings inconclusive and calls for cautious interpretation and replication."
This is where the field actually is. Not "psychedelics work brilliantly." Not "psychedelics are useless." A real signal, difficult to separate from expectancy, requiring more rigorous trials.
What the COMP360 Phase 3 trial showed
COMP360 is a synthetic formulation of psilocybin developed by COMPASS Pathways, a UK-based biopharmaceutical company. It is currently the most advanced psilocybin programme in formal regulatory development, making its trial data relevant to any discussion of where this field is actually heading.
The Phase 2b trial (COMP001), published in NEJM Evidence in 2022, remains the most substantial psilocybin dataset published to date. In 233 patients with treatment-resistant depression, a single 25mg dose produced a response rate of 37% at three weeks, compared to 8% in the 1mg comparator arm. That is a substantial difference on paper. The problems familiar from other psychedelic trials apply here too: functional unblinding was high, and the three-week follow-up captures only the early phase of any durable effect.
The Phase 3 programme (COMP005) is ongoing. As of early 2026, no efficacy data from Phase 3 has been published, and the primary readout is expected sometime in 2026 or 2027. If Phase 3 results are positive, COMPASS has stated its intention to submit for regulatory review at both the FDA and EMA. What a positive result would mean for India is less clear. Psilocybin sits under Schedule I of the Narcotic Drugs and Psychotropic Substances Act; there is no defined regulatory pathway for rescheduling or clinical authorisation at this point. Any practical availability in India, even under research conditions, is likely years away.
The honest summary: Phase 2b data is encouraging but limited. Phase 3 data does not yet exist in the public domain. The programme is closer to regulatory scrutiny than any other in this space, which is why it matters.
What This Means Clinically
In clinical practice, patients increasingly ask about psychedelics — often after reading enthusiastic coverage or hearing anecdotal accounts. The question I'm most often asked: should they try psilocybin therapy instead of, or before, conventional antidepressants?
My honest answer, informed by this research: the evidence does not currently support psychedelics as a first-line treatment. Studies showing large effect sizes were methodologically vulnerable to expectancy inflation. Current evidence on psilocybin for depression is graded as low to moderate quality, with the most consistent support for short-term antidepressant effects.
This does not mean the treatment is ineffective. It means we don't yet know how effective it is independent of the theatrical power of the drug experience itself.
Szigeti, the meta-analysis senior author, was measured on this: "I do not think psychedelics will be the silver bullet some have promised, but more than likely they will be a useful addition to the clinician's toolkit."
For patients with treatment-resistant depression who have not responded to multiple antidepressant trials, psychedelic-assisted therapy in regulated clinical settings may offer something different in mechanism and experience. For most patients presenting with moderate depression, the evidence for SSRIs — imperfect as those trials are — remains more robust, and access far more realistic, particularly in India.
What Good Research in This Area Would Look Like
The outstanding problem is methodological, not clinical. Psychedelic trials cannot be conventionally double-blinded — there is no true placebo for a profoundly psychoactive drug. Some researchers have proposed active placebos (low-dose psychedelics, niacin) to reduce expectancy differences between arms, but these approaches have their own limitations.
Until trials credibly separate pharmacological effect from expectancy effect — and measure long-term outcomes beyond 8–12 weeks — the true effect size of psychedelics for depression will remain uncertain. That is not a reason to abandon research. It is a reason to design better studies.
Conclusion
The March 2026 JAMA Psychiatry meta-analysis does not prove psychedelics are useless for depression. It demonstrates, more carefully than any previous study, that expectancy effects have been doing significant work in psychedelic trials — and that when you control for this, the pharmacological advantage over antidepressants is smaller than the headlines suggested.
Antidepressants are not vindicated here either. Their evidence base carries its own problems — industry influence, publication bias, short follow-up periods, and the washout artefact critics have identified.
What the study provides is a more honest baseline. Psychedelics may prove to be a meaningful addition to psychiatric care, particularly for treatment-resistant cases. But the "paradigm shift" framing rested on trials that couldn't properly separate drug effect from expectancy. That's a methodological problem — not a dismissal of the treatment.
FAQ
What is the FDA's current position on psychedelic-assisted therapy?
The FDA has not approved any psychedelic-assisted therapy. It has, however, granted Breakthrough Therapy Designation (BTD) to several programmes, which is a meaningful signal of institutional interest without being approval. COMPASS Pathways received BTD for psilocybin in treatment-resistant depression in 2018. Usona Institute received BTD for psilocybin in major depressive disorder in 2019. MAPS received BTD for MDMA-assisted therapy for PTSD in 2017, but the FDA rejected the New Drug Application in 2024, citing concerns about trial design and evidence quality. BTD does not mean a treatment is approved or considered safe. It means the FDA has agreed to work with the developer through an expedited review process because early evidence suggests the drug may offer a substantial improvement over available therapies. The gap between designation and approval is substantial: most BTD programmes take years to reach NDA submission. If COMP360's Phase 3 data is positive and submitted promptly, the earliest realistic window for FDA approval of a psilocybin product is probably 2027 to 2029. That timeline could move in either direction depending on data quality, submission completeness, and any additional studies the FDA requests.
Can you take psychedelics if you are already on antidepressants?
This question comes up frequently in clinical practice, and the answer has two parts: safety and efficacy. On safety, the concern depends heavily on which psychedelic is involved. For psilocybin and LSD combined with SSRIs, the theoretical risk of serotonin syndrome exists but appears low in practice. The real risk sits with ayahuasca, which contains MAOIs. Combining MAOIs with SSRIs or SNRIs carries a well-established and serious risk of serotonin syndrome, and this is not a theoretical concern. On efficacy, SSRIs appear to significantly blunt the psychedelic experience. A study from Imperial College London (Siva et al., 2024) found that chronic SSRI use reduces the subjective and psychological effects of psilocybin, most likely through 5-HT2A receptor downregulation caused by the antidepressant. In simpler terms: SSRIs and psychedelics work on overlapping biological targets, and chronic SSRI use may reduce how much effect the psychedelic actually produces. Psychedelic trials typically require a washout period of two to five weeks before administration, with the specific duration depending on the antidepressant's half-life. Fluoxetine, with its long active metabolite, requires a longer washout than sertraline or escitalopram. The practical clinical bottom line: do not stop an antidepressant unilaterally to pursue psychedelic therapy. Abrupt discontinuation carries real risks, including discontinuation syndrome and mood relapse. If you are interested in whether psychedelic-assisted therapy might be appropriate, this is a conversation to have with a psychiatrist who can weigh your specific history.
Is psychedelic-assisted therapy available in India?
No. Psilocybin and other psychedelic substances remain Schedule I controlled drugs in India. There are no approved clinical settings for psychedelic-assisted therapy. Patients interested in this area should be cautious of unregulated providers. Learn more about evidence-based treatment options available in India via teleconsultation through ManoMitra.
Does this study mean antidepressants are better than psychedelics?
Not exactly. The meta-analysis found equivalence between PAT and open-label antidepressants — not superiority of antidepressants. Both produced comparable reductions in depression scores when study design was controlled for. We don't yet have a clean head-to-head comparison that isolates pharmacological effects from expectancy effects on either side.
What is an expectancy effect, and why does it matter in psychiatric research?
An expectancy effect is the improvement in symptoms that occurs partly because a patient believes the treatment will work. It is neurobiologically real — but in trial design, it becomes a confound when you're trying to measure a drug's specific pharmacological effect. For psychedelics, the dramatic subjective experience makes expectancy effects unusually strong and hard to isolate. Read more about how psychiatric treatment evidence works on our blog.
Should I consider psychedelic therapy for my depression?
This post is educational and does not constitute individual medical advice. Current evidence suggests psychedelics are not ready for routine clinical use outside regulated research settings. If you are struggling with depression, please speak with a psychiatrist to discuss options with a well-established evidence base. Teleconsultation is available via ManoMitra if you are outside Gurgaon.
What is the Hamilton Depression Rating Scale?
The Hamilton Depression Rating Scale (HDRS) is one of the most widely used standardised measures for assessing depression severity in research and clinical settings. Scores range from 0 to 52. A reduction of 12 points is clinically significant, broadly corresponding to a shift from moderate to mild depression.
Dr. Anindo Mitra is a Consultant Psychiatrist at Athena Behavioural Health, Gurugram. He completed his MD in Psychiatry from JIPMER, Puducherry. His clinical focus includes evidence-based pharmacotherapy, deprescribing, and the neurobiology of psychiatric disorders. He writes at dranindomitra.com on mental health education for the Indian public.
This post is for educational purposes only and does not constitute individualised medical advice. If you have concerns about your mental health, please consult a qualified clinician.
